2. Academic Validation
  3. Familial cancer associated with a polymorphism in ARLTS1

Familial cancer associated with a polymorphism in ARLTS1

  • N Engl J Med. 2005 Apr 21;352(16):1667-76. doi: 10.1056/NEJMoa042280.
George Adrian Calin 1,  Francesco Trapasso,  Masayoshi Shimizu,  Calin Dan Dumitru,  Sai Yendamuri,  Andrew K Godwin,  Manuela Ferracin,  Guido Bernardi,  Devjani Chatterjee,  Gustavo Baldassarre,  Shashi Rattan,  Hansjuerg Alder,  Hideaki Mabuchi,  Takeshi Shiraishi,  Lise Lotte Hansen,  Jens Overgaard,  Vlad Herlea,  Francesca Romana Mauro,  Guillaume Dighiero,  Benjamin Movsas,  Laura Rassenti,  Thomas Kipps,  Raffaele Baffa,  Alfredo Fusco,  Masaki Mori,  Giandomenico Russo,  Chang-Gong Liu,  Donna Neuberg,  Florencia Bullrich,  Massimo Negrini,  Carlo M Croce
Affiliations

Affiliation

  • 1 Thomas Jefferson University, Philadelphia, USA.
PMID: 15843669 DOI: 10.1056/NEJMoa042280
Abstract

Background: The finding of hemizygous or homozygous deletions at band 14 on chromosome 13 in a variety of neoplasms suggests the presence of a tumor-suppressor locus telomeric to the RB1 gene.

Methods: We studied samples from 216 patients with various types of sporadic tumors or idiopathic pancytopenia, peripheral-blood samples from 109 patients with familial Cancer or multiple cancers, and control blood samples from 475 healthy people or patients with diseases Other than Cancer. We performed functional studies of cell lines lacking ARLTS1 expression with the use of both the full-length ARLTS1 gene and a truncated variant.

Results: We found a gene at 13q14, ARLTS1, a member of the ADP-ribosylation factor family, with properties of a tumor-suppressor gene. We analyzed 800 DNA samples from tumors and blood cells from patients with sporadic or familial Cancer and controls and found that the frequency of a nonsense polymorphism, G446A (Trp149Stop), was similar in controls and patients with sporadic tumors but was significantly more common among patients with familial Cancer than among those in the Other two groups (P=0.02; odds ratio, 5.7; 95 percent confidence interval, 1.3 to 24.8). ARLTS1 was down-regulated by promoter methylation in 25 percent of the primary tumors we analyzed. Transfection of wild-type ARLTS1 into A549 lung-cancer cells suppressed tumor formation in immunodeficient mice and induced Apoptosis, whereas transfection of truncated ARLTS1 had a limited effect on Apoptosis and tumor suppression. Microarray analysis revealed that the wild-type and Trp149Stop-transfected clones had different expression profiles.

Conclusions: A genetic variant of ARLTS1 predisposes patients to familial Cancer.

Figures